Our science job of the week is a Senior Quality Assurance Associate, this job has been chosen as it is:
An opportunity to join a patient focussed pharmaceutical research company with commercial, discovery, clinical and manufacturing business units collated on a single site in Hertfordshire
Commutable from Hertfordshire, Cambridgeshire & London
Strong communication is required as you will be liaising with supply chain, planning, technical, manufacturing, packaging, quality control, regulatory affairs, company network companies and others
Looking for an excellent candidate extensive knowledge and experience of Quality Assurance, Quality Systems, GMP and an understanding of manufacture and packaging of pharmaceutical products
The main purpose of this role is to ensure Quality Assurance activities relating to product support for the manufacture, packaging, testing, storage and distribution of company and third Party manufactured drug products are compliant with current GMP and Company Corporate expectations
The Engineerhas reported that Norwegian Scientists are developing carbon catalysts that could be used instead of precious metals to speed up chemical reactions.
The 3.2million EU-backed FREECATS (carbon nanostructures as metal free catalysts) project is aiming to develop environmentally friendly catalysts that can be used in fuel cells, water purification and the production of light olefins. The scientists will attempt to build carbon structures on the atomic scale that are capable of binding or transforming substances in certain ways.
Catalysis is one of the major consumers of precious metals, such as platinum. However, platinum group metals are not usually found naturally in Europe therefore European countries rely on imports. Bu using alternative catalysts Prof Magnus Rønning of Norwegian University of Science and Technology said, ‘the European dependency on precious metals will ease and therefore the dependency on less stable countries to supply these’.
The three-year project commenced in April 2012 and the team hopes the first catalysts will be available by the end of this year. There are 9 European research institutions and technology enterprises are working on the project, which is being coordinated by the Norwegian University of Science and Technology.
As reported by the EuroBiotechNews, approximately £250 million of new funding will go into life sciences across the country, a Government minister has announced.
Minister for Universities and Science, David Willetts, announced that £250M has been allocated for the first phase of several five year strategic investment programmes. This includes 26 strategic science programmes and 14 key national research capabilities, to be delivered by eight of the UK’s world-leading bioscience research institutes and their university partners. The process will be led by Britain’s Biotechnology and Biological Sciences Research Council (BBSRC).
Universities and Science Minister David Willetts told MPs during Commons Business questions on Thursday that the investment was a “commitment” to Britain’s bioscience research base. Willetts also said: “This investment will sustain excellent science at some of the UK’s leading institutes and universities. This will drive growth, support highly skilled jobs and keep the UK at the very forefront of bioscience, with benefits ranging from healthcare to energy and global food security.”
PharmPro reported that GlaxoSmithKline has announced that its Votrient (pazopanib) drug has been issued with a positive opinion by the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP).
Votrient® (pazopanib) will be used in the treatment of adult patients with selective subtypes of advanced Soft Tissue Sarcoma (STS) who have received prior chemotherapy for metastatic disease or who have progressed within 12 months after (neo) adjuvant therapy.
As part of its assessment, the CHMP reviewed safety and efficacy data from clinical studies, including one randomised, double-blind, placebo controlled, multi-centre Phase III study.
This is good news for those who have selective subtypes of advanced Soft Tissue Sarcoma.
The Telegraph have reported that GSK today, announced that it has entered an agreement to acquire Cellzome for £61 million in which they already own a 20pc stake.
Cellzome is the leader in the development and advancement of proteomics technologies. It currently has labs in Cambridge in the UK and Heidelberg in Germany. GSK currently own 19.98 % equity in the company but they will now assume full control of Cellzome. It will become part of GSK’s R&D organisation.
John Baldoni, senior vice-president of Platform & Technology Science at Glaxo, said: “The acquisition of Cellzome adds significantly to our scientific capabilities and capacity to characterise drug targets, and provides the opportunity to further enhance Glaxo’s ability to bring medicines to patients in a more effective manner.”
The process of fracking (hydraulic fracturing) involves pumping water and chemicals into shale rock at high pressure to extract gas. Energy companies say the use of fracking will lead to cheaper supplies.
The chairman of the Environment Agency Lord Smith told BBC Radio 4’s Today programme that he would not stand in the way of fracking in the UK, as long as certain requirements were met, arguing that “it could be part of the answer” to the UK’s energy demands.
He also said “the source of a domestically available gas supply would, of course, be potentially very beneficial for our energy needs. It could provide energy security, which we don’t necessarily have when we import gas from abroad. It could be affordable,”
Fierce Biotech reported that The National Institutes of Health today unveiled a collaborative program that will match researchers with a selection of pharmaceutical industry compounds to help scientists explore new treatments for patients.
NIH’s new National Center for Advancing Translational Sciences (NCATS) has partnered initially with Pfizer, AstraZeneca, and Eli Lilly. The drug companies will offer up their data and investigators will have a chance to explore new uses, with a set of deal templates in place to help speed the process on 20 programs.
The investigators will have access to failed drugs to see if they can be repurposed for new uses.
Rod MacKenzie, group senior vice president, head of Pfizer PharmaTherapeutics Research and Development said “Pfizer has a rich history of partnering with the academic and public sectors to discover and develop innovative medicines…We believe that participating in this unique program, and making well researched molecules available to NIH’s broad network of researchers, is another important step in advancing a vibrant biomedical ecosystem.”
Nolato have bought Cope Allman Jaycare for an initial SEK 179 million (USD $26 million) and a deferred consideration based on earnings up to and including the first quarter of 2014.
Cope Allman Jaycare has a history within pharmaceutical packaging dating back to 1958. The company has 270 employees at its plants in Portsmouth and Newcastle. They have annual sales of around SEK 270 million (USD $39 million), and its customers comprise of a number of international pharmaceutical companies.
Christer Wahlquist, president of Nolato Medical, in a press release said “Nolato already has a strong position in the Scandinavian pharmaceutical packaging market…….This acquisition gives us a local presence in the UK, which is an important part of the global pharmaceutical industry. It also opens doors with a large number of leading international pharmaceutical companies, which are existing customers of Cope Allman Jaycare.”
This is Leicester reported that the long awaited development of the Leicester science park will receive a kick start as plans are set to be approved this week.
On Tuesday, Leicester City Council’s development control committee will discuss the development which planning officers have recommended for approval. The hope is that this park could provide 100’s of new jobs in the area, the scheme also includes a new supermarket to be built on land next to the science park site, which as it is understood will be run by Asda.
The first stage of the development is likely to cost £37 million but if planning consent is given tomorrow then the park could be finished by the end of the year. A city council planning spokesman said: “The proposal would have many significant positive regeneration impacts for the science park and the wider area.”
Naynesh Mistry at CK Science is currently recruiting for a Senior R&D Scientist to join a leading manufacturer and supplier of clinical microbiology instrumentation in their product development team on a permanent basis in the North West
This Senior R&D Scientist role will be to conduct research into and develop a wide range of new products for diagnostic microbiology with an emphasis on establishing novel molecular diagnostics.
As a Senior R&D Scientist you will carry out investigations related to both the improvement of existing products, and the improvement of manufacturing procedures and resolution of manufacturing problems, as well as working towards the achievement of recognition of significant new products through publication and presentation of external evaluations.
The primary focus of research will be the development of novel targets and probes for pathogenic micro-organisms with an emphasis on pathogens in human clinical disease.
The successful applicant will be expected to play a leading role in the development of a portfolio of molecular assays integrating a novel platform with forefront diagnostic assay.
Qualifications and skills required:
The ideal candidate for this Senior R&D Scientist role will have a knowledge of nucleic amplification and extraction techniques is essential, combined with experience in conventional microbiological diagnostic methods. Experience of primer design and bioinformatics software and databases would be advantageous
Ideally, candidates should have MSc or PhD in appropriate discipline or equivalent, as well as experience in commercial and/or academic research facilities, and be committed to continuous learning and professional development.
How to apply:
For more information or to apply for this Senior R&D Scientist role please contact Naynesh Mistry on 0114 2839956 or email email@example.com. Please quote reference SH23878 in all correspondence.
Heather Deagle at CK Science is currently recruiting for several Analytical Chemist’s (more senior roles available too) to join a major biotechnology company at their site in the North East of England. These roles will be on a temporary contract for initially 6-12 months with a strong possibility of becoming permanent.
The ideal candidate for this Analytical Chemist role will have proven experience in working in an analytical laboratory type role involving method qualification or validation, release testing of drug substances or stability testing.
The successful candidate for this Analytical Chemist role ideally will be qualified to Degree level or similar in a relevant scientific discipline and have some experience gained with in a GMP setting.
For more information or to apply for this Analytical Chemist role please contact Heather Deagle at CK Science on 0191 384 8905 or email firstname.lastname@example.org. Please quote reference DH23844 in all correspondence.
Barney Smithat CK Science is currently recruiting for a Technical Specialist in analytical chemistry to join a company that provides analytical services for the oil, gas, environmental and petrochemical industries to be based in the North East of England.
As a Technical Specialist with extensive knowledge and experience in analytical instrumentation such as GC, GC-MS, ICP, AA, UV, IR and KF, you will provide technical support and troubleshooting in instrumentation installation, validation, method development and maintenance to laboratories UK wide. You will work with company Laboratory, Technical and QA Managers on instrumentation projects and provide technical support to other departments.
Qualifications and skills:
The successful candidate for this Technical Specialist role must be qualified to minimum HNC/HND in chemistry or related subject or possess equivalent commercial experience. It is essential that you have an in-depth knowledge and proven track record in method development, validation and instrumentation maintenance within analytical chemistry.
Scottish Power released a press statement today announcing that it expects to invest over £5billion to upgrade the electricity network in central and southern Scotland over the next 10 years, and is launching a recruitment drive to boost its engineering and technical workforce by creating 300 new roles.
These new roles will include full-time system design roles, high-voltage, direct current (HVDC) development jobs, and transmission and distribution engineers. It is anticipated there will be around 50 new apprenticeships created and the graduate programme will look to take in at least 50 new graduates by 2013.
Four out of five energy industry employees are set to retire over the next 15 years. In this time more than £200bn will be invested in the UK energy sector, with tens of thousands of engineers required to deliver the work. To address this skills gap, ScottishPower is also investing £6.5 million in grassroots skills development between 2011 and 2013.
First Minister Alex Salmond said: “Three hundred new high-skilled jobs for Scotland’s energy sector is very encouraging news indeed. Scottish Power’s £6.5 million commitment is further proof of the continued long term investment by global companies in Scotland’s fast growing renewables industry.
Naynesh Mistry at CK Science is currently looking to recruit 2 x Formulation Development Scientists to join an international pharmaceutical organisation to work at their site in Northern Ireland on a permanent basis.
As a Formulation Development Scientist, the post holder will be directly involved in the development of all aspects of the processes used in the manufacture of new and existing drug products (dosage forms will include tablets and capsules)
The post holder will:
Assume direct involvement in the process development for the manufacture of medicinal products based in a range of dosage forms including tablets, capsules, controlled release systems, liquids and semi-solids.
Operate the various pieces of equipment involved in the process, at laboratory, pilot and commercial scale
Complete accurate process documentation in accordance with GMP, to include manufacturing documents and preparation of reports
Participate in transfer of technology from formulation development to production; liaising with production to ensure smooth transfer of information
Liaise with production in relation to manufacture of clinical trial batches
Participate in critical interpretation of experimental data
Participate in practical problem solving in relation of on-going and new projects
Qualifications and skills required:
The ideal candidate for this Formulation Development Scientist role would have a Bachelors degree (or equivalent) in a Scientific/Technical discipline.
Essential requirements are as follows:
Experience in solid dosage manufacturing
Previous experience of pharmaceutical drug product manufacturing techniques such as dry powder blending, granulation, encapsulation and tablet compression
Previous experience of completing batch processing instructions in accordance with GMP
Experience in cGMP audits and knowledge of Microsoft Office (Word, Office, Excel etc)
For more information or to apply for these Formulation Development Scientist roles please contact Naynesh Mistry on 0114 283 9956 or email email@example.com. Please quote reference SH23782 in all correspondence.
Boehringer Ingelheim is sponsoring a part time St Johns Ambulance liaison officer to provide free first aid training in schools. Natasha Bright will be available to the schools at little or no cost to carry out training, before schools had to pay for training, so the initiative will save them hundreds of pounds or mean more taking advantage of first aid training.
Boehringer Ingelheim’s involvement in free first aid training started in 2009 when, in liaison with the Bracknell News and St John, it launched free Childlifesaver courses for readers to learn basic skills required to save a baby or toddler’s life.
Duncan Cantor, director of communications at Boehringer, said: “As a company, we are committed to family health. This year is the 50th anniversary of the opening our UK office and what better way to celebrate our half-century in Bracknell than by extending the work we have already done in the first aid arena to local children. By helping them to learn the basic first aid skills they may, one day, be in a position to save someone’s life and that, for me, is a pretty good legacy for any company to have.”
Victoria Walker at CK Science is currently recruiting for a Technical Support Coordinator to join a waste management and used oil company based in South Yorkshire in their Waste Services team. To find out more, please watch Victoria’s short video below:
For more information or to apply for this Technical Support Coordinator role please contact Victoria Walker on 0114 283 9956 or email firstname.lastname@example.org. Please quote reference SH23722 in all correspondence.